EUVIMEDEUVIMED entdecken
Open Access

GLP1 receptor agonism alters growth and therapeutic response in prostate cancer

Soumen Bera, Lisa C Gutgesell, Brynne Darden, Robert M Sargis iD, Mark Maienschein-Cline, Charles E Gaber, Natalie M Reizine, Donald J Vander Griend, Jordan E Vellky iD

Endocrine-Related Cancer · 2025

DOI: 10.1530/erc-25-0185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Soumen Bera und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The University of Illinois Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Prostatic Neoplasms, Glucagon-Like Peptides, Glucagon-Like Peptide-1 Receptor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The burgeoning metabolic benefits of GLP1 receptor (GLP1R) agonists have led to their widespread use for treatment of type 2 diabetes mellitus and obesity. While the pharmacological GLP1R agonist semaglutide primarily activates GLP1R signaling in the pancreas, GLP1R is also expressed in advanced prostate cancer where GLP1R agonism could directly alter cellular signaling. Because metabolic disorders and their treatment are common among those with prostate cancer, understanding the effects of semaglutide in prostate cells is critical for deciphering its systemic effects and delineating potential impacts on prostate cancer outcomes. In prostate cancer models, semaglutide decreased cell proliferation, glycolytic function, and phosphokinase-mediated signaling. This overall suppression of signaling downstream of GLP1R is consistent with inhibitory GPCR signaling, which was confirmed by reduced cAMP levels. Furthermore, cell proliferation was decreased with semaglutide alone and in combination with enzalutamide, supporting that GLP1R agonism may provide therapeutic benefit as a standalone treatment or to augment the therapeutic benefits of androgen receptor signaling inhibitors. Interestingly, in a trans-differentiation model (n = 55), GLP1R and AR expression were negatively correlated, while GLP1R and NEPC markers (DLL3, ASCL1) were positively correlated, suggesting an association between GLP1R and neuroendocrine differentiation. Bioinformatic analyses on publicly available patient RNA sequencing data (n = 664) identified significantly higher GLP1R expression in advanced prostate cancer vs benign prostate, where it was associated with negative Notch signaling. Taken together, our data support a model wherein GLP1R agonism blocks oncogenic signaling pathways and growth of prostate cancer cells, which could be exploited therapeutically for men with advanced prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsProstatic NeoplasmsGlucagon-Like PeptidesGlucagon-Like Peptide-1 ReceptorMaleHumansCell ProliferationAnimalsBenzamidesNitrilesMiceCell Line, TumorGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

advanced prostate cancercastration-resistant prostate cancerincretin mimeticsmetabolic co-morbiditiesneuroendocrine prostate cancer

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesBenzamidesNitrilesGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Pathology, The University of Illinois Chicago, Chicago, Illinois, USA.
  • School of Life Sciences, B S Abdur Rahman Crescent Institute of Science and Technology, Chennai, Tamil Nadu, India.
  • Graduate Program in Pathology, The University of Illinois Chicago, Chicago, Illinois, USA.
  • Portal to Biomedical Research Careers Postbaccalaureate Research Education Program (PBRC-PREP), Chicago, USA.
  • Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, The Univeristy of Illinois Chicago, Chicago, Illinois, USA.
  • University of Illinois at Chicago Research Informatics Core, Chicago, USA.

ORCID-Profile: Robert M Sargis, Jordan E Vellky

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Bera, S., Gutgesell, L. C., Darden, B., Sargis, R. M., Maienschein-Cline, M., Gaber, C. E., Reizine, N. M., Vander Griend, D. J., & Vellky, J. E. (2025). GLP1 receptor agonism alters growth and therapeutic response in prostate cancer. Endocrine-Related Cancer. https://doi.org/10.1530/erc-25-0185

Vancouver

Bera S, Gutgesell LC, Darden B, Sargis RM, Maienschein-Cline M, Gaber CE, et al. GLP1 receptor agonism alters growth and therapeutic response in prostate cancer. Endocrine-Related Cancer. 2025. doi:10.1530/erc-25-0185

BibTeX
@article{Bera2025,
  author = {Bera, Soumen and Gutgesell, Lisa C and Darden, Brynne and Sargis, Robert M and Maienschein-Cline, Mark and Gaber, Charles E and Reizine, Natalie M and Vander Griend, Donald J and Vellky, Jordan E},
  title = {GLP1 receptor agonism alters growth and therapeutic response in prostate cancer},
  journal = {Endocrine-Related Cancer},
  year = {2025},
  doi = {10.1530/erc-25-0185}
}
Kostenlos starten →